Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Feature|Articles|May 21, 2026
The LBAs to Watch for at the 2026 ASCO Meeting
Fact checked by: Sabrina Serani
Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.
Advertisement
Advertisement
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting kicks off on May 29th, 2026, in Chicago. This year’s theme is The Science and Practice of Translation: Improving Cancer Outcomes Worldwide, and over 200 presentations will serve to complement. Here, we’ve outlined some of the most anticipated late-breaking abstracts (LBAs) set to be presented during the meeting.
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Advertisement
Advertisement